News | Tomotherapy | December 13, 2019

Timpanogos Cancer Services First in Utah to Offer Radiation Treatments with the Accuray Radixact System

System is designed to improve treatment results, minimize treatment impact on patients' quality of life

Timpanogos Cancer Services made history in Utah recently with the installation of the state's first Radixact System, the next-generation tomotherapy platform

December 13, 2019 — Timpanogos Cancer Services made history in Utah recently with the installation of the state's first Radixact System, the next-generation tomotherapy platform. Accuray Incorporated's Radixact System is one of the most versatile systems available, enabling the administration of radiation using a range of delivery methods including image-guided, intensity-modulated radiation therapy (IG-IMRT) and stereotactic body radiation therapy (SBRT), that provide the hospital's clinical team with the flexibility to offer a personalized and precise treatment approach to almost anyone requiring treatment with radiation.

Timpanogos Cancer Services is part of the MountainStar Healthcare family of hospitals, a division of Hospital Corporation of America (HCA). Being part of this vast, nearly 300-hospital network helps Timpanogos Regional Hospital to achieve its goal of offering the highest quality of care to its patients.

Following a ribbon-cutting ceremony to commemorate the Radixact System installation, James W. Clarke M.D., a board certified radiation oncologist and Timpanogos Cancer Services director, shared how he believes the system will benefit the hospital's patients. "The Radixact System will enable our team to truly provide our patients with the best treatment for them. The treatment planning and delivery capabilities of the system allow for the highest level of precision with maximal sparing of the nearby normal tissues. The system's unique hardware and software will facilitate the treatment of organ-confined tumors, locally advanced tumors and metastatic tumors. It will also provide us with the tools to assess whether adaptation of radiation delivery during the course of treatment is needed because of changes in tumor size and patient anatomy. We look forward to using the Radixact System to efficiently deliver precise and accurate radiation treatments to more patients each day."

"We are proud to have the opportunity to partner with the Timpanogos Cancer Services clinical team to help advance cancer care in Utah. The response from our Radixact System users has been overwhelmingly positive as they have been able to expand patient access to precision radiation therapy, enabling previously untreatable cases to be treated with ease – and with a single, seamless process," said Joshua H. Levine, president and CEO at Accuray. "The unique Radixact System technology facilitates the delivery of both conventionally fractionated and hypofractionated radiation therapy treatments on a single platform, enabling the clinical team to treat a wide range of cancer cases. We believe this will be extremely valuable as reimbursement models shift favoring hypofractionation, when clinically appropriate. With the installation of the Radixact System, the Timpanogos team is well positioned to achieve their goal of providing world class radiation therapy treatments to their growing patient base."

For more information: www.accuray.com

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...